SCHEMBL4190671

SCHEMBL4190671

CCCCCCNC(=O)COc1nc(-c2ccc(C(=O)O)cc2)sc1C

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 7)

geneUniProtsupporting neighboursconfidence
RARB P10826 12/20 1.00
RARG P13631 4/20 1.00
RARA P10276 3/20 0.59
CSNK2A2 P19784 3/20 0.46
CSNK2A1 P68400 3/20 0.46
DHODH Q02127 1/20 0.44
ALOX5 P09917 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4196901 0.96 RARB (0.92) RARBRARGRARACSNK2A2CSNK2A1
SCHEMBL4190248 0.84 RARB (0.73) RARBRARGRARACSNK2A2CSNK2A1
SCHEMBL4178560 0.79 RARB (0.67) RARBRARG
SCHEMBL4188775 0.78 RARB (1.00) RARBRARGRARACSNK2A2CSNK2A1
SCHEMBL4190628 0.77 RARB (0.63) RARBRARGRARA
SCHEMBL4187456 0.77 RARB (0.62) RARBRARGRARACSNK2A2CSNK2A1
SCHEMBL4184893 0.76 RARB (0.62) RARBRARGRARA
SCHEMBL4326646 0.76 RARB (0.62) RARBRARGRARA
SCHEMBL4183477 0.76 RARB (0.62) RARBRARGRARACSNK2A2CSNK2A1
SCHEMBL4178994 0.76 RARB (0.66) RARBRARGRARACSNK2A2CSNK2A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220296579-A1 COMPOSITIONS AND METHODS FOR PROVIDING CARDIOPROTECTIVE EFFECTS CORNELL UNIVERSITY (US) 2022-09-22 US disclosed
US-11191755-B2 Compositions and methods for providing cardioprotective effects CORNELL UNIVERSITY (US) 2021-12-07 US disclosed
US-11160769-B2 Methods of treating metabolic syndrome related conditions using retinoic acid receptor agonists CORNELL UNIVERSITY (US) 2021-11-02 US disclosed
US-20090176837-A1 COMPOUNDS WITH ACTIVITY AT RETINOIC ACID RECEPTORS SONY CORPORATION (JP) 2009-07-09 US disclosed
US-20090176837-A1 COMPOUNDS WITH ACTIVITY AT RETINOIC ACID RECEPTORS SONY CORPORATION (JP) 2009-07-09 US disclosed
US-20090176837-A1 COMPOUNDS WITH ACTIVITY AT RETINOIC ACID RECEPTORS SONY CORPORATION (JP) 2009-07-09 US disclosed
EP-1907347-A2 COMPOUNDS WITH ACTIVITY AT RETINOIC ACID RECEPTORS Arcadia Pharmaceuticals Inc. (US) 2008-04-09 EP disclosed
WO-2007009083-A2 COMPOUNDS WITH ACTIVITY AT RETINOIC ACID RECEPTORS ACADIA PHARMACEUTICALS INC. (US) 2007-01-18 WO disclosed
WO-2007009083-A2 COMPOUNDS WITH ACTIVITY AT RETINOIC ACID RECEPTORS ACADIA PHARMACEUTICALS INC. (US) 2007-01-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220296579-A1 COMPOSITIONS AND METHODS FOR PROVIDING CARDIOPROTECTIVE EFFECTS RARB, RARG, RARA RARB 1/4885RARG 2/4885RARA 3/4885
US-11191755-B2 Compositions and methods for providing cardioprotective effects RARB, RARG, RARA RARB 1/4885RARG 2/4885RARA 3/4885
US-11160769-B2 Methods of treating metabolic syndrome related conditions using retinoic acid receptor agonists RARA, RARG, RXRA RARB 5/4885RARG 2/4885RARA 1/4885
US-20090176837-A1 COMPOUNDS WITH ACTIVITY AT RETINOIC ACID RECEPTORS RARB, RARA, RARG RARB 1/4885RARG 3/4885RARA 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.